Abstract 4218
Background
BC at a young age is generally associated with poor prognosis, more aggressive treatment, long-term toxicities, and unique psychosocial concerns. Little data is available on outcomes defined by molecular profiles. We characterized BCSS in female patients (pts)
Methods
RS results were provided electronically to SEER (US population based cancer registries) per their linkage methods (Petkov et al, npj Breast Cancer, 2016). Eligible pts were diagnosed (Jan 2004 - Dec 2012) with N0 HR+ BC, and had no prior malignancy or multiple tumors. BCSS was analyzed for female pts
Results
1,761 of 7,186 pts
Conclusions
This large population-based study of N0 HR+ HER2- BC indicates not all young women have aggressive tumor biology and poor prognosis. Nearly half (47%) of women
Clinical trial identification
Legal entity responsible for the study
National Cancer Institute
Funding
National Cancer Institute
Disclosure
S. Shak: Full-time employee of Genomic Health and a shareholder of Genomic Health. D. Miller: Employee of Genomic Health. All other authors have declared no conflicts of interest.